The σ1 receptor agonist 4-PPBP elicits ERK1/2 phosphorylation in primary neurons: A possible mechanism of neuroprotective action

Neuropharmacology

Volumn 59, Issue 6, 2010, Pages 416-424

  Tan, F ^a   Guio Aguilar, P L ^a   Downes, C ^a   Zhang, M ^a   O'Donovan, L ^a   Callaway, J K ^a   Crack, P J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

4 PPBP; MAP kinase pathway; Neuroprotection; PRE 084; Primary mouse neuronal cultures; Sigma 1 ( 1) receptor

Indexed keywords

1 PHENYLCYCLOHEXANECARBOXYLIC ACID 2 MORPHOLINOETHYL ESTER; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 PHENYL 1 (4 PHENYLBUTY)PIPERIDINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; N [2 (3,4 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; OPIATE AGONIST; SIGMA OPIATE RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN CORTEX; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HIPPOCAMPUS; IMMUNOFLUORESCENCE; IN VITRO STUDY; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT ANTIBODY TECHNIQUE; HALOPERIDOL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MORPHOLINES; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; RECEPTORS, SIGMA;

EID: 77956901188     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.05.014     Document Type: Article

References (38)

1. Ajmo C.T., Vernon D.O.L., Collier L., Pennypacker K.R., Cuevas J. Sigma receptor activation reduces infarct size at 24 hours after permanent middle cerebral artery occlusion in rats. Current Neurovascular Research 2006, 3:89-98.
2. Aydar E., Palmer C.P., Klyachko V.A., Jackson M.B. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 2002, 34(3):399-410.
3. Bhardwaj A., Sawada M., London E.D., Koehler R.C., Traystman R.J., Kirsch J.R. Potent σ1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine modulates basal and N-methyl-D-aspartate-evoked nitric oxide production in vivo. Stroke 1998, 29:2404-2411.
4. Bouschet T., Perez V., Fernandez C.l., Bockaert J., Eychene A., Journot L. Stimulation of the ERK pathway by GTP-loaded Rap1 requires the concomitant activation of Ras, protein kinase C, and protein kinase A in neuronal cells. The Journal of Biological Chemistry 2003, 278:4778-4785.
5. Cobos E.J., Baeyens J.M., Del Pozo E. Phenytoin differentially modulates the affinity of agonist and antagonist ligands for sigma 1 receptors of guinea pig brain. Synapse 2005, 55:192-195.
6. Cobos E.J., Lucena G., Baeyens J.M., Del Pozo E. Differences in the allosteric modulation by phenytoin of the binding properties of the sigma1 ligands [3H](+)-pentazocine and [3H]NE-100. Synapse 2006, 59:152-161.
7. A receptor: functional domains implicated by mutational analysis. Frontiers in Bioscience 1996, 1:214-233.
8. DeCoster M.A.B., Klette K.L., Knight E.S., Tortella F.C. Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Research 1995, 671:45-53.
9. Dirnagl U., Iadecola C., Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends in Neurosciences 1999, 22:391-397.
10. Franceschini D., Giusti P., Skaper S.D. MEK inhibition exacerbates ischemic calcium imbalance and neuronal cell death in rat cortical cultures. European Journal of Pharmacology 2006, 553:18-27.
11. Glennon R.A., Yousif M.Y., Ismaiel A.M., El-Ashmawy M.B., Herndon J.L., Fischer J.B., Server A.C., Howie K.J.B. Novel 1-phenylpiperazine and 4-phenylpiperidine derivatives as high-affinity σ ligands. Journal of Medicinal Chemistry 1991, 34:3360-3365.
12. Goyagi T., Goto S., Bhardwaj A., Dawson V.L., Hurn P.D., Kirsch J.R. Neuroprotective effect of σ1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is linked to reduced neuronal nitric oxide production. Stroke 2001, 32:1613-1620.
13. Guitart X., Codony X., Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology 2004, 174:301-319.
14. Guzman-Lenis M.S., Navarro X., Casas C. Selective sigma receptor agonist 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons. Neuroscience 2009, 162:31-38.
15. Haddad J.J. Hypoxia and the regulation of mitogen-activated protein kinases: gene transcription and the assessment of potential pharmacologic therapeutic interventions. International Immunopharmacology 2004, 4:1249-1285.
16. Hansen M.B., Nielsen S.E., Berg K. Reexamination and further development of a precise and rapid dye method for measuring cell growth/cell kill. Journal of Immunological Methods 1989, 119:203-210.
17. Harukuni I., Bhardwaj A., Shaivitz A.B., DeVries C., London E.D., Hurn P.D., Traystman R.J., Kirsch J.R. σ1-Receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine affords neuroprotection from focal ischemia with prolonged eperfusion. Stroke 2000, 31:976-982.
18. 2+ concentration. Journal of Pharmacology and Experimental Therapeutics 2000, 293:788-798.
19. Hayashi T., Su T.P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007, 131:596-610.
20. Hurtado O., Pradillo J.M., Alonso-Escolano D., Lorenzo P., Sobrino T., Castillo J., Lizasoain I., Moro M.A. Neurorepair versus neuroprotection in stroke. Cerebrovascular Disease 2006, 21(suppl 2):54-63.
21. 1 receptors. European Journal of Pharmacology 1997, 340:169-175.
22. Katnik C., Guerrero W.R., Pennypacker K.R., Herrera Y., Cuevas J. Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia. Journal of Pharmacology and Experimental Therapeutics 2006, 319:1355-1365.
23. Kim W.-K., Chung J.-H., Kim H.-C., Ko K.H. Nitric oxide-enhanced excitotoxity-independent apoptosis of glucose-deprived neurons. Neuroscience Research 1999, 33:281-289.
24. Marrazzo A., Caraci F., Salinaro E.T., Su T.-P., Copani A., Ronsisvalle G. Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. Neuropharmacology and Neurotoxicology 2005, 16:1223-1226.
25. Mullen R.J., Buck C.R., Smith A.M. NeuN, a neuronal specific nuclear protein in vertebrates. Development 1992, 116:201-211.
26. Puente B.D., Nadal X., Portillo-Salido E., Sanchez-Arroyos R., Ovalle S., Palacios G., Muro A., Romero L., Entrena J.M., Baeyens J.M., Lopez-Garcia J.A., Maldonado R., Zamanillo D., Vela J.M. Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain 2009.
27. Su T.-P., Wu X.-Z., Cone E.J., Shukla K., Gund T.M., Dodge A.L., Parish D.W. Sigma Compounds Derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand. The Journal of Pharmacology and Experimental Therapeutics 1991, 259:543-550.
28. Takebayashi M., Hayashi T., Su T.-P. σ-1 receptors potentiate epidermal growth factor signaling towards neuritogenesis in PC12 cells: potential relation to lipid raft reconstitution. Synapse 2004, 53:90-103.
29. Takahashi H., Kirsch J.R., Hashimoto K., London E.D., Koehler R.C., Traystman R. PPBP [4-phenyl-1-(4-phenylbutyl) piperidine], a potent σ-receptor ligand, decreases brain injury after transient focal ischemia in cats. Stroke 1995, 26:1676-1682.
30. Takahashi H., Kirsch J.R., Hashimoto K., London E.D., Koehler R.C., Traystman R. PPBP [4-phenyl-1-(4-phenylbutyl) piperidine] decreases brain injury after transient focal ischemia in rats. Stroke 1996, 27:2120-2123.
31. Takahashi H., Traystman R.J., Hashimoto K., London E.D., Kirsch J.R. Postischemic brain injury is affected stereospecifically by pentazocine in rats. Anesthesia & Analgesia 1997, 85:353-357.
32. Taylor J.M., Ali U., Iannello R.C., Hertzog P., Crack P.J. Diminished Akt phosphorylation in neurons lacking glutathione peroxidase-1 (Gpx1) leads to increased susceptibility to oxidative stress-induced cell death. Journal of Neurochemistry 2005, 92:283-293.
33. Vagnerova K., Hurn P.D., Bhardwaj A., Kirsch J.R. Sigma 1 receptor agonists act as neuroprotective drugs through inhibition of inducible nitric oxide synthase. Anesthesia & Analgesia 2006, 103:430-434.
34. Wada T., Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004, 23:2838-2849.
35. Wayne R., Flegal K., Friday G., Furie K., Go A., Greenlund K., Haase N., Ho M., Howard V., Kissela B., Kittner S., Lloyd-Jones D., McDermott M., Meigs J., Moy C., Nichol G., O'Donnell C.J., Roger V., Rumsfeld J., Sorlie P., Steinberger J., Thom T., Wasserthiel-Smoller S., Hang Y. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:69-171.
36. Yang S., Bhardwaj A., Cheng J., Alkayed N.J., Hurn P.D., Kirsch J.R. Sigma receptor agonists provide neuroprotection in vitro by preserving bcl-2. Anesthesia & Analgesia 2007, 104:1179-1184.
37. York R.D., Yao H., Dillon T., Ellig C.L., Eckert S.P., McCleskey E.W., Stork P.J.S. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 1998, 392:622-626.
38. Zhang H., Cuevas J. σ Receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. Journal of Pharmacology and Experimental Therapeutics 2005, 313(3):1387-1396.